For laboratory research use only. Not for human or veterinary use. This is educational reference information, not medical advice.
Research Database / Peptides / BPC-157
BPC-157 · Body Protection Compound 157

BPC-157

Derived from a partial sequence of human gastric juice protein BPC; characterized in preclinical studies from the 1990s.
Recovery & Regeneration
Overview Research Publications Laboratory FAQ References
Overview
Scientific nameBody Protection Compound 157
SynonymsBepecin; PL 14736
AbbreviationBPC-157
CAS Number137525-51-0
Molecular formulaC62H98N16O22
Molecular weight1419.53 g/mol (average)
Sequence (one-letter)GEPPPGKPADDAGLV
Length15 residues
OriginSynthetic pentadecapeptide fragment
PubChem CID9941957
2D / 3D structure
2D chemical structure of BPC-157

Interactive sequence

Select a residue to see its amino acid.
Research Summary

Mechanisms under investigation

The following are areas of ongoing preclinical investigation. They describe hypotheses and observations reported in the literature, not established clinical effects.

Angiogenesis SignalingNitric Oxide PathwayVEGFR2 Pathway

Target receptors / systems studied

Nitric Oxide SynthaseVEGFR2
Evidence tiers below reflect how much has been studied in each model type. Counts describe research volume — they do not indicate proven efficacy, safety, or clinical consensus.

Evidence base (transparent counts)

Cellular studies 3 publications
Animal studies 4 publications
Human observational reports 1 publication
Controlled human trials 0 publications
Review articles 2 publications

Research timeline

  • 1991 — Body Protection Compound family described from gastric juice protein.
  • 1999 — Early preclinical characterization of the BPC-157 fragment in animal models.
  • 2010 — Expanded studies of angiogenic and connective-tissue endpoints in rodents.
  • 2020 — Mechanistic (VEGFR2 and nitric oxide) and cellular-model investigations plus reviews.
Publication Library

Selected literature

Filter by study model. Each record is classified for the evidence base above.

2023
Limited low-certainty observational reportHuman · human
2019
Influences cell migration markers in vitroCellular · fibroblast culture
2019
Narrative review of tissue healing mechanismsReview
2018
Synthesis of BPC-157 preclinical pharmacology and healing mechanismsReview · PubMed (30584171)
2014
Promotes tendon fibroblast outgrowth via growth hormone receptor in vitroCellular · fibroblast culture · PubMed (25415472)
2014
Muscle healing endpoints in a rodent modelAnimal · mouse
2012
Accelerates muscle-to-bone healing in a rat injury modelAnimal · rat · PubMed (22611364)
2007
Angiogenic and VEGFR2-linked tissue repair in rodent injuryAnimal · rat · PubMed (17494668)
2003
Modulates nitric oxide system in cultured endothelial cellsCellular · endothelial culture · PubMed (12645866)
2001
Gastric mucosa protection in rodent ulcer modelsAnimal · rat · PubMed (11678507)

Each record maps to a structured evidence row with study model, species, and support level.

Laboratory Information

Handling and reference

Storage

Lyophilized: store at -20 C protected from light. Reconstituted: refrigerate and use within the reported stability window.

Stability

Lyophilized powder is comparatively stable; reconstituted solutions are more labile and sensitive to temperature and freeze-thaw.

Solubility

Reported soluble in water and bacteriostatic water for laboratory preparation; contains no cysteine disulfide bridges.

Handling

Use aseptic technique; swirl gently rather than vortexing. For in vitro / research use only.

Molecular weight calculator

Average-mass estimate from a one-letter sequence.

Reconstitution calculator

Laboratory concentration only. Not dosing guidance.

Frequently Asked Questions
What is BPC-157?
BPC-157 is a synthetic pentadecapeptide derived from a partial sequence of human gastric juice protein BPC, studied in preclinical (cellular and animal) research models. For laboratory research use only.
What research models has it been studied in?
The literature indexed here is predominantly cellular (in vitro) and animal studies. See the evidence base and publication library above for the transparent counts by study model.
Is there controlled human clinical trial evidence?
Controlled human clinical trials are counted separately in the evidence base above. Cellular and animal findings do not establish human clinical effects.
How is it stored and handled in a laboratory?
Lyophilized: store at -20 C protected from light. Reconstituted: refrigerate and use within the reported stability window.
Is this intended for human use?
No. All information and materials are for laboratory research use only — not for human or veterinary use, and not intended to diagnose, treat, cure, or prevent any disease.
References and Citation

Evidence records

  1. Limited low-certainty observational report (2023) — observational.
  2. Influences cell migration markers in vitro (2019) — in vitro.
  3. Narrative review of tissue healing mechanisms (2019) — review.
  4. Synthesis of BPC-157 preclinical pharmacology and healing mechanisms (2018) — review — PubMed.
  5. Promotes tendon fibroblast outgrowth via growth hormone receptor in vitro (2014) — in vitro — PubMed.
  6. Muscle healing endpoints in a rodent model (2014) — in vivo.

Every record carries a study model, species, support level and review status in the evidence table.

Citation generator

Loading citation...

Explore the full research database

Browse peptide profiles, publications, and laboratory references — all research-only.

For laboratory research use only. Not for human or veterinary use. Educational reference information — not medical advice.